ReproCELL Incorporated (4978.T)
JPY 142.0
(-3.4%)
JPY 142.0
(-3.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -31.41 Million JPY | 89.71% |
| 2022 | -305.31 Million JPY | 46.91% |
| 2021 | -575.09 Million JPY | 29.23% |
| 2020 | -812.57 Million JPY | 20.06% |
| 2019 | -1.01 Billion JPY | -69.02% |
| 2018 | -601.42 Million JPY | 72.31% |
| 2017 | -2.17 Billion JPY | -138.25% |
| 2016 | -911.66 Million JPY | 53.52% |
| 2015 | -1.96 Billion JPY | -334.13% |
| 2014 | -451.79 Million JPY | -237.35% |
| 2013 | -133.92 Million JPY | -2381.87% |
| 2012 | 5.86 Million JPY | 126.43% |
| 2011 | -22.2 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -75 Million JPY | 5.95% |
| 2023 Q1 | 72.06 Million JPY | 127.11% |
| 2023 FY | -31.41 Million JPY | 89.71% |
| 2023 Q4 | -79.74 Million JPY | -539.57% |
| 2023 Q3 | -12.46 Million JPY | -10.7% |
| 2023 Q2 | -11.26 Million JPY | -115.63% |
| 2022 Q1 | 42.35 Million JPY | 118.93% |
| 2022 FY | -305.31 Million JPY | 46.91% |
| 2022 Q4 | -265.82 Million JPY | -146.04% |
| 2022 Q3 | -108.04 Million JPY | -512.47% |
| 2022 Q2 | 26.19 Million JPY | -38.16% |
| 2021 FY | -575.09 Million JPY | 29.23% |
| 2021 Q4 | -223.76 Million JPY | -49.36% |
| 2021 Q3 | -149.81 Million JPY | -88.61% |
| 2021 Q2 | -79.43 Million JPY | 34.94% |
| 2021 Q1 | -122.08 Million JPY | 20.91% |
| 2020 Q2 | -157.9 Million JPY | 24.11% |
| 2020 FY | -812.57 Million JPY | 20.06% |
| 2020 Q1 | -208.06 Million JPY | 41.0% |
| 2020 Q3 | -292.25 Million JPY | -85.09% |
| 2020 Q4 | -154.35 Million JPY | 47.19% |
| 2019 Q3 | -227.79 Million JPY | -10.49% |
| 2019 FY | -1.01 Billion JPY | -69.02% |
| 2019 Q4 | -352.63 Million JPY | -54.8% |
| 2019 Q1 | -229.93 Million JPY | -34.23% |
| 2019 Q2 | -206.15 Million JPY | 10.34% |
| 2018 FY | -601.42 Million JPY | 72.31% |
| 2018 Q4 | -171.3 Million JPY | 14.95% |
| 2018 Q3 | -201.41 Million JPY | -35.64% |
| 2018 Q2 | -148.49 Million JPY | -85.12% |
| 2018 Q1 | -80.21 Million JPY | 94.72% |
| 2017 Q1 | -200.81 Million JPY | 45.36% |
| 2017 Q4 | -1.51 Billion JPY | -601.29% |
| 2017 Q3 | -216.72 Million JPY | 7.64% |
| 2017 Q2 | -234.65 Million JPY | -16.85% |
| 2017 FY | -2.17 Billion JPY | -138.25% |
| 2016 Q1 | -346.16 Million JPY | 73.24% |
| 2016 FY | -911.66 Million JPY | 53.52% |
| 2016 Q4 | -367.55 Million JPY | -948.16% |
| 2016 Q3 | 43.33 Million JPY | 117.96% |
| 2016 Q2 | -241.27 Million JPY | 30.3% |
| 2015 Q3 | -269.14 Million JPY | 7.29% |
| 2015 Q2 | -290.31 Million JPY | -167.97% |
| 2015 Q1 | -108.33 Million JPY | 12.6% |
| 2015 Q4 | -1.29 Billion JPY | -380.61% |
| 2015 FY | -1.96 Billion JPY | -334.13% |
| 2014 Q1 | -41.04 Million JPY | -28.29% |
| 2014 Q4 | -123.95 Million JPY | 37.47% |
| 2014 Q3 | -198.24 Million JPY | -123.88% |
| 2014 Q2 | -88.54 Million JPY | -115.74% |
| 2014 FY | -451.79 Million JPY | -237.35% |
| 2013 FY | -133.92 Million JPY | -2381.87% |
| 2013 Q3 | -26.05 Million JPY | 36.73% |
| 2013 Q1 | -34.69 Million JPY | 0.0% |
| 2013 Q2 | -41.17 Million JPY | -18.69% |
| 2013 Q4 | -31.99 Million JPY | -22.79% |
| 2012 FY | 5.86 Million JPY | 126.43% |
| 2011 FY | -22.2 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 108.181% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 94.038% |
| GNI Group Ltd. | 8.09 Billion JPY | 100.388% |
| Linical Co., Ltd. | 338.26 Million JPY | 109.287% |
| Trans Genic Inc. | 4.08 Million JPY | 869.033% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 97.815% |
| Soiken Holdings Inc. | -662.2 Million JPY | 95.256% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 122.739% |
| AnGes, Inc. | -7.43 Billion JPY | 99.578% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 97.561% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 99.563% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 116.827% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 95.972% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 97.275% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 97.402% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 96.133% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 90.294% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 97.425% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 97.791% |
| PeptiDream Inc. | 3.03 Billion JPY | 101.035% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 98.379% |
| Ribomic Inc. | -1.02 Billion JPY | 96.933% |
| SanBio Company Limited | -2.64 Billion JPY | 98.812% |
| Healios K.K. | -3.82 Billion JPY | 99.178% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 97.311% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 97.891% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 97.802% |
| StemRIM | -2.02 Billion JPY | 98.446% |
| CellSource Co., Ltd. | 923.14 Million JPY | 103.403% |
| FunPep Company Limited | -933.41 Million JPY | 96.634% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 96.322% |
| Stella Pharma Corporation | -763.74 Million JPY | 95.887% |
| TMS Co., Ltd. | -960.04 Million JPY | 96.728% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 97.22% |
| Cuorips Inc. | -632.18 Million JPY | 95.031% |
| K Pharma,Inc. | 260.33 Million JPY | 112.067% |
| Takara Bio Inc. | 1.48 Billion JPY | 102.123% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 219.095% |
| StemCell Institute Inc. | 310.98 Million JPY | 110.102% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 121.943% |
| CellSeed Inc. | -846.53 Million JPY | 96.289% |